Innovative Approaches in Cancer Treatment at the World ADC Conference
Oxford BioTherapeutics, a clinical-stage oncology company, is poised to share exciting developments in the field of cancer treatment at the World ADC Conference. With its Chief Medical Officer Dr. Harald Haeske leading the discussion, the company plans to unveil new strategies that combine Antibody Drug Conjugates (ADCs) with immune checkpoint inhibitors, aiming to enhance therapeutic efficacy for patients battling advanced cancers.
Key Presentation Highlights
At the World ADC Conference taking place in San Diego from 4 to 7 November, Dr. Haeske will serve as a featured speaker. He will provide insights into combination therapy strategies, detailing the advancements of OBT’s promising lead asset, OBT076. This innovative ADC is being developed to combat advanced solid tumors, which often present significant treatment challenges.
Exploration of Combination Therapies
Dr. Haeske expressed enthusiasm about sharing the company’s approach to pairing ADCs with immune checkpoint inhibitors. He emphasizes that this combination could lead to breakthroughs for patients facing difficult-to-treat cancers, notably enhancing overall treatment outcomes.
Advances in Target Discovery
In addition to Dr. Haeske's session, Dr. Yu-Tzu Tai, an expert in ADC and translational research at OBT, will discuss the company’s advanced discovery platform, OGAP-Verify. This platform is designed for the identification of innovative, cancer-specific targets, paving the way for first-in-class therapy development. It is especially significant for ADCs, T-cell engagers, and therapeutic antibodies, thereby addressing critical unmet needs within oncology.
Pushing Boundaries in Oncology
Using OGAP-Verify, OBT has made strides in pinpointing unique oncology targets, drawing from an extensive database of over 5,000 cancer cell proteins. This not only affirms OBT's focus on innovative research but also its dedication to developing new therapies that meet the needs of cancer patients worldwide.
About Oxford BioTherapeutics
Oxford BioTherapeutics, known for its commitment to advancing cancer treatments, specializes in first-in-class immuno-oncology and ADC-based therapies. The company’s pipeline is robust, featuring several programs designed to address key patient needs in oncology.
OBT's lead program, OBT076, has entered expansion in clinical trials targeting patients with advanced or refractory solid tumors, including those types linked to CD205 overexpression. These trials have gained momentum, reinforcing the therapeutic potential that OBT076 holds for patients.
Backed by a strong management team and strategic partnerships with leading industry names, including Boehringer Ingelheim and ImmunoGen, Oxford BioTherapeutics continues to validate its development capabilities in the oncology sector.
Frequently Asked Questions
What will be discussed at the World ADC Conference?
The conference will focus on innovative strategies for combining ADCs with immune checkpoint inhibitors, as well as the advancements in OBT’s target discovery platform, OGAP-Verify.
Who is presenting at the conference?
Dr. Harald Haeske, the Chief Medical Officer of Oxford BioTherapeutics, and Dr. Yu-Tzu Tai, Associate Director of ADC & Translational Research, will be presenting key findings.
What is OBT076?
OBT076 is Oxford BioTherapeutics' lead ADC asset, designed to treat advanced solid tumors and is currently in clinical trials.
How does OGAP-Verify work?
OGAP-Verify is a target discovery platform that utilizes data from a vast cancer membrane proteomic database to identify novel oncology targets for therapeutic development.
How has OBT established its presence in the industry?
OBT has formed strategic partnerships with several leading companies, which helps to enhance its capabilities in developing innovative oncology therapies.
